$CBLL

Foehr David sold $18K of CBLL

Foehr David (Senior VP, Finance and PAO) sold 987 shares of Ceribell, Inc. (CBLL) at $18.00 on 2026-05-21 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Foehr David
Published May 26, 2026, 8:18 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 26, 2026, 8:25 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$CBLL
Neutral
high confidence
Mentioned
$CBLL
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CBLLNeutralLow
01

Why it matters

Because the trade is explicitly under a 10b5-1 plan, it generally reduces the likelihood that the sale is reacting to newly available material information; therefore, fundamental repricing is unlikely absent other news.

02

Market read

Insider selling disclosure for CBLL with a 10b5-1 plan; typically low trading impact unless corroborated by broader negative signals.

03

What to watch

The disclosure does not state motives; traders may want to compare with prior Form 4 patterns and total insider ownership trend rather than one transaction.

Relevance 6/10Timing: Filed 2026-05-26 for a trade dated 2026-05-21; any tape impact would be around the filing window.

Background

The article is an SEC Form 4 insider transaction filing (open-market sale) for Ceribell, Inc. (CBLL) by an officer, executed under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$CBLLNeutralHigh confidence
Context

Ceribell (CBLL) disclosed an open-market sale by its Senior VP, Finance and PAO: 987 shares sold at $18.00 on 2026-05-21 under a 10b5-1 plan.

Expected impact

Limited near-term impact; any reaction is likely small and short-lived unless paired with other company-specific news.

Evidence & confidence

SEC Form 4 shows a scheduled 10b5-1 sale rather than an opportunistic trade tied to new information, and the article contains no operational/financial catalysts.

Market effects

Minimal—single-insider 10b5-1 sales rarely reset sector expectations for diagnostics/biotech.

None indicated; this is company-specific insider activity.

None indicated; no international deal/regulatory development mentioned.

Counterpoint

If insiders repeatedly sell outside of 10b5-1 or at unusually high frequency, it could be interpreted as elevated risk appetite reduction—even if this specific sale is scheduled.

Key entities

  • Ceribell, Inc.

    CBLL disclosed an officer’s 10b5-1 open-market sale of 987 shares at $18.00 on 2026-05-21.

  • Foehr David

    Senior VP, Finance and PAO; sold shares directly and reported holdings after the transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CBLLHigh

Ceribell, Inc. (CBLL): Results of Operations and Financial Condition

Ceribell, Inc. (CBLL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Ceribell Reports Second Quarter 2026 Financial Results Sunnyvale, Calif. – August 10, 2026 – CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today repor